CLINICAL TRIALS PROFILE FOR EFFEXOR
✉ Email this page to a colleague
505(b)(2) Clinical Trials for EFFEXOR
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Dosage | NCT05875610 ↗ | Preventive Approach Using Venlafaxine | Recruiting | Mit Ghamr Oncology Center | Phase 4 | 2023-05-01 | Peripheral and Motor neuropathy represent a main obstacle for a better quality of life for cancer patients, Venlafaxine is introduced in a new dosing regimen for treating of oxaliplatin and taxanes induced peripheral neuropathy in cancer patients. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for EFFEXOR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00001483 ↗ | Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression | Completed | National Institute of Mental Health (NIMH) | Phase 2 | 1995-06-01 | This study will compare the effectiveness of relatively new antidepressants which have different mechanisms of action. Buproprion (Wellbutrin) works on dopamine and the dopaminergic pathway. Sertraline (Zoloft) works as a selective serotonin reuptake inhibitor (SSRI). Venlafaxine (Effexor) works as a mixed serotonin, norepinephrine, and dopamine reuptake inhibitor. Subjects enrolled in this study will be patients diagnosed with a bipolar disorder who are presently taking medication to prevent the symptoms of the disease (prophylactic treatment), but have had breakthrough episodes of depression despite taking their medication. Patients will receive any one of the three antidepressant medications as noted above plus a placebo inactive sugar pill, in order to mask which antidepressant is being prescribed) in addition to their regular medication for bipolar disorder. All of the doses will be calculated as effective for the treatment of a unipolar major depressive disorder. The patient will continue receiving the medication for ten weeks. The effectiveness of the drug treatment will be measured by using three different scales; 1. Inventory for Depressive Symptoms - Clinicians form (IDS-C) 2. Clinical Global Impression scale(CGI-BP) 3. Life Charting Methodology (LCM) Patients who do not respond to their medication within ten weeks from the beginning of the study will be considered as non-responders and be offered the opportunity to start the study again, taking one of the two remaining medications. For example, if a patient was assigned to take Wellbutrin but it was ineffective, he/she could re-enter the study and be given either Zoloft or Effexor. Patients that do respond in the first ten weeks of the study will be eligible to continue taking the medication for one year to assess the long term effectiveness of the drug on preventing episodes of depression and to assess for any possible differential induction of mania. |
| NCT00043550 ↗ | Treatments for Depression: Drug Versus Psychotherapy | Completed | National Institute of Mental Health (NIMH) | Phase 3 | 2001-11-01 | This 4-8 month study, with a 2-year follow up period, will compare sertraline (Zoloft®), venlafaxine (Effexor®), supportive-expressive psychotherapy, and placebo to determine which is more effective in treating major depression. |
| NCT00043550 ↗ | Treatments for Depression: Drug Versus Psychotherapy | Completed | University of Pennsylvania | Phase 3 | 2001-11-01 | This 4-8 month study, with a 2-year follow up period, will compare sertraline (Zoloft®), venlafaxine (Effexor®), supportive-expressive psychotherapy, and placebo to determine which is more effective in treating major depression. |
| NCT00045916 ↗ | Optimizing Electroconvulsive Therapy for Depression | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 2001-02-01 | This study will evaluate the effectiveness of electroconvulsive therapy (ECT) administered with medication for the treatment of a major depressive episode (unipolar or bipolar) and will compare two types of ECT. |
| NCT00045916 ↗ | Optimizing Electroconvulsive Therapy for Depression | Completed | New York State Psychiatric Institute | Phase 4 | 2001-02-01 | This study will evaluate the effectiveness of electroconvulsive therapy (ECT) administered with medication for the treatment of a major depressive episode (unipolar or bipolar) and will compare two types of ECT. |
| NCT00046020 ↗ | Study Evaluating Venlafaxine ER in Recurrent Depression | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 | 2000-08-01 | The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression |
| NCT00086190 ↗ | Study of Antidepressants in Parkinson's Disease | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 3 | 2005-06-01 | The purpose of this study is to find out if two antidepressant medications, paroxetine and venlafaxine, can help control depression in Parkinson's disease, and if these medications affect the motor symptoms of Parkinson's disease such as tremor, stiffness, slowness, and balance. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for EFFEXOR
Condition Name
Clinical Trial Locations for EFFEXOR
Trials by Country
Clinical Trial Progress for EFFEXOR
Clinical Trial Phase
Clinical Trial Sponsors for EFFEXOR
Sponsor Name
